Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity.

Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

Abstract: The present invention pertains to novel uses of endomorphine-1 peptide, analogs, and salts thereof for therapy of children, patients currently suffering from drug addiction, patients prone to opioid addiction, and patients with chemo-induced pain.

Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

Abstract: The invention is a method for identifying markers associated with the presence of a predetermined characteristic comprising accumulating spectral data from a sample known to have a predetermined characteristic, identifying a spectral feature which is indicative of the predetermined characteristic, and identifying a marker associated with the spectral feature.

Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.

Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

Abstract: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity.

Abstract: The present invention relates to a method for determining whether a first biological sample is infected with one of HIV and hepatitis. The first biological sample is obtained from a first mammal. A first and second parameter are compared. A difference between the parameters is indicative of whether the first sample is infected with at least one of HIV and hepatitis. The first parameter is obtained from a fluorescence emission spectrum that results from a first fraction of the first biological sample, the first biological sample having been fractionated into the first fraction and a second fraction. The first fraction includes a greater relative amount of lipoprotein than the second fraction. The second parameter is obtained from a fluorescence emission resulting from a second biological sample obtained from a second, different mammal. The first and second fluorescence emissions are essentially free of fluorescence emission resulting from substances not-native to the first and second mammals, respectively.

Abstract: The subject invention pertains to compositions and methods of treatment of angiogenesis using PF4 and peptide fragments thereof.

Abstract: The subject invention pertain to methods of treating Kaposi's Sarcoma and ocular neovascularization using rPF4 and angiogenesis-inhibiting fragments of rPF4.

Abstract: The gene encoding the ligninase rLDM.TM. 6 has been cloned and expressed. The ligninases produced via the processes disclosed herein are useful to degrade or modify lignin in pulp operations.

Abstract: Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of a purified heparin binding fragment of PF4 or of recombinant PF4.

Abstract: Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of purified PF4 or rPF4 or a heparin neutralizing fragment thereof.

Abstract: Disclosed are tetraphenyl porphyrins which are beta-substituted by fluoro or chloro and/or bear electronegative substituents on the phenyl including one or two water solubilizing substituents. The new porphorins are particularly suitable as catalysts in a variety of oxidative reactions and methods.

Abstract: Disclosed are tetraphenyl porphyrins which are beta-substituted by fluoro or chloro and/or bear electronegative substituents on the phenyl including one or two water solubilizing substituents. The new porphorins are particularly suitable as catalysts in a variety of oxidative reactions and methods.